Newsfeeds - Spark Newswire

2 minute read

Innovation Passport Granted For CRN04777 For The Treatment Of Congenital Hyperinsulinism

October 6, 8:13 AM

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted CRN04777 an "Innovation Passport" for the

CRNX

7 minute read

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

May 26, 12:15 PM

On Thursday, 94 companies set new 52-week lows.

ACOR

6 minute read

88 Biggest Movers From Yesterday

By Lisa Levin

May 26, 5:08 AM

Gainers The Very Good Food Company Inc. (NASDAQ: VGFC) shares jumped 118.2% to close at $0.2950 on Wednesday as the company announced it increased retail distribution across Canada with Loblaw Companies.

ADXN

1 minute read

SVB Leerink Maintains Outperform on Crinetics Pharmaceuticals, Raises Price Target to $39

By Benzinga Newsdesk

May 26, 4:52 AM

SVB Leerink analyst Joseph Schwartz maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Outperform and raises the price target from $36 to $39.

CRNX

1 minute read

Crinetics Pharmaceuticals Announces Positive Top-line Results From CRN04894 Early-Stage Trial

By Ragothaman Srinivasan

May 25, 9:11 AM

Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) revealed positive topline results from a first-in-human Phase 1 clinical study of CRN04894 for the treatment of patients with Cushing's disease.

CRNX

3 minute read

The Daily Biotech Pulse: Third FDA Rejection For Verrica’s Skin Disease Drug, Assembly Bio Terminates Hepatitis B Virus Pact, Consistency Data For Valneva’s Chikungunya Vaccine

By Vandana Singh

May 25, 8:46 AM

Here's a roundup of top developments in the biotech space over the last 24 hours.

ASMB

4 minute read

53 Biggest Movers From Yesterday

By Lisa Levin

April 1, 4:18 AM

Gainers

AFIB

1 minute read

Crinetics’ CRN04777 Shows Dose-Dependent Suppression of Fasting Insulin

By Vandana Singh

March 31, 9:38 AM

Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) announced topline results from the multiple ascending dose (MAD) cohorts of healthy volunteers in the Phase 1…

CRNX

1 minute read

Crinetics Pharmaceuticals Q4 EPS $(0.68) Down From $(0.66) YoY

By Benzinga Newsdesk

March 30, 4:02 PM

Crinetics Pharmaceuticals (NASDAQ:CRNX) reported quarterly losses of $(0.68) per share. This is a 3.03 percent decrease over losses of $(0.66) per share from the same period last year.

CRNX

4 minute read

52 Biggest Movers From Yesterday

By Lisa Levin

December 1, 5:08 AM

ACET